Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04135781
Other study ID # CSPC-KAL-GC-04
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 1, 2020
Est. completion date October 31, 2024

Study information

Verified date March 2020
Source Zhejiang Cancer Hospital
Contact Cheng xiangdong, PhD
Phone 0571-88128041
Email Chengxd516@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting


Description:

This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting. The primary endpoint is the 3-year diseases-free survival (DFS) rate. The secondary endpoints are the overall survival (OS) and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 616
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Age of 18-75 years;

2. Histological diagnosis of stage III gastric adenocarcinoma and Gastroesophageal junction of the stomach;

3. Patients are required to provide a pathologically confirmed diagnosis report and provide 4-5 histological white films obtained at baseline;;

4. Patients underwent D2 radical resection within 6 weeks prior to random enrollment; and R0 resection criteria were achieved;

5. Ability to perform chemotherapy within 7 days of enrollment in the randomized group;

6. No prior anti-tumor treatment (including systemic chemotherapy and local radiotherapy), except for initial gastrectomy for primary lesions;

7. ECOG performance status of 0-1;

8. Haematological status: absolute neutrophil count(ANC) =1.5×109 /L, platelet count(PLT) =100×109 /L, hemoglobin(HB) =90 g/L;WBC =3.0×109 /L;And no bleeding tendency;

9. Liver function: alanine glutamate transaminase (ALT) and glutamate transaminase (AST) =2.5 x upper limit of normal range (ULN), alkaline phosphatase =2.5 x upper limit of normal range (ULN);total bilirubin (TBIL)=1.5 x upper limit of normal range (ULN), or=3 x upper limit of normal range (ULN) when with Gilbert's syndrome;

10. kidney function: Creatinine(Cr)=1.5 x upper limit of normal range(ULN) or Creatinine clearance >60 ml/min (calculated according to Cockroft-Gault)

11. Able and willing to comply with the study plans in this protocol and sign the informed consent;

Exclusion Criteria:

1. Treat with any other study drug or participate in another clinical trial with therapeutic intent within 28 days prior to enrollment;

2. postoperative complications requiring clinical intervention and affecting treatment, such as stomach cramps, dumping syndrome;

3. Patients known to be allergic or intolerant to clinical trial drugs;

4. investigator believes will affect the subject's treatment regimen, uncontrolled serious medical diseases, including severe heart disease (such as the New York Heart Association (NYHA) Level II or more Congestive heart failure), cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, uncontrolled infection;

5. Known active infection with HIV, hepatitis B or hepatitis C;

6. Other serious and uncontrolled non-malignant disease; except adequately treated cervical carcinoma in situ, non-melanoma skin Localized prostate cancer after cancer and radical surgery (PSA = 10 ng/ml); no recurrence or metastasis was found based on imaging follow-up results and any disease-specific tumor markers;

7. accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation;

8. Female patients during pregnancy or lactation, who are refused to receive contraception during the childbearing age;

9. The investigator judges patients who are not suitable for the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
nab paclitaxel
nab paclitaxel (120mg/m2;iv;d1,8)
Tegafur
S-1 (<1.25 m2, 40 mg; 1.25 to =1.5 m2, 50 mg; and = 1.5 m2, 60 mg;po;d1-14 bid)
Oxaliplatin
Oxaliplatin(130mg/m2 , iv, d1)
Capecitabine
Capetabine(1000 mg/m2 po, d1-14 bid )

Locations

Country Name City State
China Zhejiang Cancer Hospital;Cancer hospital of the university of chinese academy of sciences Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital CSPC Ouyi Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3 years Diseases-free Survival rate(3 years-DFS) DFS is defined as time from the date of inclusion up to the date of disease progression or death up to 3 years
Secondary Overall survival (OS) Overall survival is defined as time from the start of treatment until death due to any reason. up to 3 years
Secondary Safety as measured by number and grade of adverse events Summary adverse events according to NCI-CTCAE 5.0 up to 3 years
See also
  Status Clinical Trial Phase
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT02604979 - The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study N/A
Active, not recruiting NCT00394433 - Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer Phase 2
Completed NCT00201747 - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Phase 2
Completed NCT00215514 - Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma Phase 0
Recruiting NCT04486651 - HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer Phase 3
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Recruiting NCT04526470 - Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer Phase 1/Phase 2
Completed NCT01257711 - A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer N/A
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Withdrawn NCT03704077 - An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Phase 2
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Recruiting NCT05489250 - The PLATON Network
Completed NCT02547064 - Effect of Modified Stylet Angulation on the Intubation With GlideScope® N/A
Withdrawn NCT00800969 - Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach Phase 2
Completed NCT00296322 - Trial of Adjuvant Chemotherapy for Gastric Cancer Phase 3
Recruiting NCT04215861 - Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy
Recruiting NCT06199895 - Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Phase 2
Recruiting NCT01038154 - Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Phase 4